Elevated β2-M expression is associated with the progression of human prostate cancer 22, breast cancer 23, renal cancer 24, lung cancer 25, colon cancer 26 and a number of liquid tumors such as multiple myeloma, lymphoma and leukemia 3. Here, B2M is linked to plasma cell myeloma.